All In Biotech

Drug Trial Radar · NCT06263348

A Post-Marketing Safety Study of Dorzagliatin in Patients With Type 2 Diabetes

A Multicenter Post-Marketing Observational Study to Evaluate the Long-Term Safety of Dorzagliatin in Patients With Type 2 Diabetes Mellitus

Last checked: Nov 20, 2026Latest source record: Jul 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

2,024

Actual

Start

Jan 17, 2024

Primary completion

Dec 31, 2025

Study completion Apr 30, 2026

Sponsor

Lead sponsor
Hua Medicine LimitedIndustry
Sponsor type
Industry
Collaborators
Kun Tuo Xincheng Pharmaceutical Researchand Development(Beijing)Co.,Ltd.
First posted
Feb 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the long-term safety of Dorzagliatin in a larger population of type 2 diabetes mellitus patients by collecting the post-marketing clinical safety data of Dorzagliatin.

Conditions

  • Type2diabetes

Interventions

  • Dorzagliatin tabletsDrug

    During the study, patients should follow the dosing instructions from the investigator, which are made according to the package insert and the patients' conditions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidences of ADRs and SAEsTime frame: 52 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.